Home » Stocks » AZN

AstraZeneca plc (AZN)

Stock Price: $58.41 USD -0.43 (-0.73%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
Market Cap 154.86B
Revenue (ttm) 27.58B
Net Income (ttm) 3.96B
Shares Out 2.63B
EPS (ttm) 1.52
PE Ratio 38.54
Forward PE 23.53
Dividend $2.80
Dividend Yield 4.79%
Trading Day June 16
Last Price $58.41
Previous Close $58.84
Change ($) -0.43
Change (%) -0.73%
Day's Open 58.86
Day's Range 58.28 - 59.34
Day's Volume 6,964,685
52-Week Range 46.48 - 63.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

5 hours ago - Zacks Investment Research

AstraZeneca Covid Antibody Cocktail Only 33% Effective

Jun.15 -- AstraZeneca Plc's antibody cocktail was only 33% effective at preventing symptomatic Covid-19 in people who had been exposed to the virus, failing a study that was key to the drugmaker's pande...

1 day ago - Bloomberg Markets and Finance

AstraZeneca plc (LON:AZN) released its ‘Storm Chaser' study results on Tuesday that at first glance appear disappointing but beyond the headline takeaway, there were some positives. The trial assessed b...

1 day ago - Invezz

AstraZeneca Plc (NASDAQ: AZN) reported data from the STORM CHASER Phase 3 trial showing that its long-acting antibody (LAAB) combination AZD7442 did not meet the primary endpoint of post-exposure preven...

1 day ago - Benzinga

The monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.

1 day ago - Forbes

Shares don't always rise, but dividend income is as steady as it gets. These dividend stocks are great long-term, despite recent weaknesses.

Other stocks mentioned: FCX, MRK, SBUX, VZ, WFG, WMT
2 days ago - InvestorPlace

The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.

2 days ago - Zacks Investment Research

BOSTON, June 8, 2021 /PRNewswire/ -- PathAI, a global leader of AI-powered technology applied to pathology, today announced that new data highlighting a quality control tool for HER2 testing in digital ...

1 week ago - PRNewsWire

Are you looking for stocks that have been beaten up in recent weeks? Here are seven stocks to buy right now at the start of the summer.

Other stocks mentioned: ADBE, BIIB, DPZ, ILMN, ORLY, VZ
1 week ago - InvestorPlace

NetScientific PLC's (LON:NSCI), up 235 at 92p, was the top riser after striking a licensing deal with AstraZeneca PLC (LON:AZN). Its ProAxsis subsidiary is to work with AstraZeneca over the validation a...

1 week ago - Proactive Investors

NetScientific PLC's (LON:NSCI) ProAxsis subsidiary has struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vac...

1 week ago - Proactive Investors

Astrazeneca (AZN) closed at $56.80 in the latest trading session, marking a +0.98% move from the prior day.

1 week ago - Zacks Investment Research

AstraZeneca Plc's (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years in patients with unresectable Stage III non-s...

1 week ago - Benzinga

AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cance...

Other stocks mentioned: MRK
1 week ago - Benzinga

AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the US...

Other stocks mentioned: ALXN
1 week ago - Proactive Investors

Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.

Other stocks mentioned: ALXN
1 week ago - Reuters

AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned ...

Other stocks mentioned: CTLT
1 week ago - Benzinga

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have...

Other stocks mentioned: BNTX, DYAI, JNJ
2 weeks ago - OTC PR Wire

Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types o...

2 weeks ago - Benzinga

AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with moderate to severe systemic lupus erythem...

2 weeks ago - Benzinga

MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molec...

2 weeks ago - Business Wire

Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.

Other stocks mentioned: BBH, BNTX, BTEC, CVAC, FBT, IBB, MRNA ...
2 weeks ago - Zacks Investment Research

EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

Other stocks mentioned: ALXN
2 weeks ago - Reuters

These pharmaceutical companies might make great long-term additions to your portfolio.

Other stocks mentioned: GSK
2 weeks ago - The Motley Fool

AstraZeneca Plc's (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved t...

2 weeks ago - Benzinga

Fast-growing AstraZeneca might make an interesting addition to your portfolio.

2 weeks ago - The Motley Fool

Several of these vaccine makers face challenges.

Other stocks mentioned: JNJ, NVAX
2 weeks ago - The Motley Fool

AstraZeneca PLC (LON:AZN) said Tagrisso has been approved in the EU for the adjuvant treatment of adult patients with a type of early-stage lung cancer. It targets epidermal growth factor receptor-mutat...

2 weeks ago - Proactive Investors

After the almighty ding-dong over executive pay at AstraZeneca PLC (LON:AZN) earlier this month, two more high-profile companies are in the firing line over their executive pay schemes. Legal & General ...

2 weeks ago - Proactive Investors

German scientists at Goethe University have claimed to know why some COVID-19 vaccines can cause blood clots. AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) have both developed DNA-based for...

Other stocks mentioned: JNJ
2 weeks ago - Proactive Investors

AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029...

Other stocks mentioned: ALXN
2 weeks ago - Proactive Investors

The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU's lawyer, Rafael Jafferali, asked the court to fo...

3 weeks ago - Benzinga

Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro said that the contract was for filling the shot into vials a...

3 weeks ago - Benzinga

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

Other stocks mentioned: ALXN
3 weeks ago - Proactive Investors

The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition a...

Other stocks mentioned: ALXN
3 weeks ago - Benzinga

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

Other stocks mentioned: ALXN
3 weeks ago - Proactive Investors

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has received the final US$40mln from a US$80mln cash and equity investment from AstraZeneca, adding that it expects to be working on up to five tar...

Other stocks mentioned: SLN
3 weeks ago - Proactive Investors

Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewh...

Other stocks mentioned: ALXN
3 weeks ago - Reuters

AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.

3 weeks ago - Zacks Investment Research

In this week's coronavirus (COVID-19) vaccine news, the UK has reached the 60mln milestone of administered doses.  That includes 22mln people having received both shots required to complete the immunisa...

Other stocks mentioned: BNTX, PFE
3 weeks ago - Proactive Investors

Along with the approval of Moderna's COVID-19 vaccine, Japan's regulatory authority has also approved AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria for adults. According to Japan's public ...

3 weeks ago - Benzinga

Japan has approved the COVID-19 vaccines produced by Moderna Inc (NASDAQ:MRNA) and by AstraZeneca PLC (LON:AZN) in conjunction Oxford University, for people aged over 18. Japan has so far only vaccinate...

Other stocks mentioned: MRNA
3 weeks ago - Proactive Investors

AstraZeneca PLC (LON:AZN) announced that the COVID-19 vaccine developed with Oxford University has been granted special approval for emergency use in Japan in people aged over 18. The jab, now called Va...

3 weeks ago - Proactive Investors

AstraZeneca PLC's (LON;AZN) Covid-19 vaccine gives between 85-90% effectiveness after two shots, Public Health England said today after analysing data from those inoculated so far. That puts the Astra/O...

3 weeks ago - Proactive Investors

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 20...

3 weeks ago - Business Wire

AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating Fasenra (benralizumab) in adult patient...

4 weeks ago - Benzinga

AstraZeneca PLC (NASDAQ:AZN) is in the spotlight today, after the Financial Times reported that the company's Covid-19 vaccine works well as a third booster shot, according to a study by Oxford Universi...

4 weeks ago - Schaeffers Research

Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter. A th...

4 weeks ago - Benzinga

Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million pounds earlier. The com...

Other stocks mentioned: OXBDF
4 weeks ago - Benzinga

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...

Other stocks mentioned: OXBDF
4 weeks ago - GlobeNewsWire

About AZN

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 12, 1993
CEO
Pascal Soriot
Employees
76,100
Stock Exchange
NASDAQ
Ticker Symbol
AZN
Full Company Profile

Financial Performance

In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 63.60, which is an increase of 8.89% from the latest price.

Price Target
$63.60
(8.89% upside)
Analyst Consensus: Buy